Insulin products commissioner of health costs review authorization; excess costs determination; maximum reimbursement level establishment; appropriation. This bill establishes a process for the commissioner of health to review the cost of insulin products made available for sale in the state, determine if the cost of a product has led or
will lead to excess costs for health care systems in the state, and establish a maximum level of reimbursement for an insulin product that the commissioner finds has led or will
lead to excess costs for health care systems. Excess cost is defined as a cost that is not sustainable to public and private health care systems over a ten-year period.